Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.
David Kuter, MD, DPhil
Advertisement
David Kuter, MD, DPhil, is director of clinical hematology at Massachusetts General Hospital and professor of medicine at Harvard Medical School.
Articles by David Kuter, MD, DPhil
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
2
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
3
Contributor: Why Public Health Keeps Failing—and How to Fix It
4
Stool-Based DNA Testing Leads to Timely Colonoscopy in Rural, Urban Populations
5
